| Alfred S Guirguis, DO | |
|
6700 W 95th St, Suite 330, Oak Lawn, IL 60453-2199 | |
| (708) 422-3242 | |
| (708) 422-3243 |
| Full Name | Alfred S Guirguis |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 24 Years |
| Location | 6700 W 95th St, Oak Lawn, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063539211 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | 036-108495 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Palos Community Hospital | Palos heights, IL | Hospital |
| Elmhurst Memorial Hospital | Elmhurst, IL | Hospital |
| Osf Little Company Of Mary Medical Center | Evergreen park, IL | Hospital |
| Advocate Good Samaritan Hospital | Downers grove, IL | Hospital |
| Advocate Christ Hospital & Medical Center | Oak lawn, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Affiliated Oncologists Llc | 2365606563 | 36 |
News Archive
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.
A little bitter with a little sweet, in the form of a nano-complex dietary supplement taken before meals, can result in a substantial reduction of fat and sugar absorption in the body, Hebrew University of Jerusalem and Harvard University researchers have found.
› Verified 5 days ago
| Entity Name | Affiliated Oncologists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225314362 PECOS PAC ID: 2365606563 Enrollment ID: O20120620000456 |
News Archive
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.
A little bitter with a little sweet, in the form of a nano-complex dietary supplement taken before meals, can result in a substantial reduction of fat and sugar absorption in the body, Hebrew University of Jerusalem and Harvard University researchers have found.
› Verified 5 days ago
| Entity Name | Gynecological Cancer Institute Of Chicago Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114318474 PECOS PAC ID: 2365769437 Enrollment ID: O20150330001321 |
News Archive
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.
A little bitter with a little sweet, in the form of a nano-complex dietary supplement taken before meals, can result in a substantial reduction of fat and sugar absorption in the body, Hebrew University of Jerusalem and Harvard University researchers have found.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alfred S Guirguis, DO 6700 W 95th St, Suite 330, Oak Lawn, IL 60453-2199 Ph: (708) 422-3242 | Alfred S Guirguis, DO 6700 W 95th St, Suite 330, Oak Lawn, IL 60453-2199 Ph: (708) 422-3242 |
News Archive
Sinapis Pharma, Inc. has successfully completed a Bridge financing to continue to support its drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.
Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.
DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.
A little bitter with a little sweet, in the form of a nano-complex dietary supplement taken before meals, can result in a substantial reduction of fat and sugar absorption in the body, Hebrew University of Jerusalem and Harvard University researchers have found.
› Verified 5 days ago
Mrs. Anne Ziellnski Schaible, MD Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 4400 W 95th St, Ste 403, Oak Lawn, IL 60453 Phone: 708-422-3984 Fax: 708-423-5733 | |
Antoinette Kitch, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 9555 S 52nd Ave Ste E, Oak Lawn, IL 60453 Phone: 708-423-2300 | |
Carrie Allison Mcilwain, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6700 W 95th St Ste 330, Oak Lawn, IL 60453 Phone: 708-422-3242 Fax: 708-422-3243 | |
Dr. Tejas Sheth, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5851 W 95th St, Suite 400, Oak Lawn, IL 60453 Phone: 708-857-7230 Fax: 708-425-5779 | |
Dr. Michael Howard Savin, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4440 W 95th St, Suite 207, Oak Lawn, IL 60453 Phone: 708-684-5340 Fax: 708-684-3355 | |
Dr. Mary Jane A. Nowak, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 9540 Southwest Hwy, Suite A, Oak Lawn, IL 60453 Phone: 312-513-7700 |